Multiple Myeloma: all 3,712 studies
Page 34 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00477815Phase 1
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic MalignanciesCompletedNCT00477035Phase 1
- Long-Term Follow Up Study for AMD3100 PatientsCompletedNCT00476294
- Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell TransplantTerminatedNCT00469820Phase 1
- Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell TransplantationCompletedNCT00461955Phase 2
- GEM05 for Patients With Multiple Myeloma Under 65 YearsCompletedNCT00461747Phase 3
- Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological MalignanciesCompletedNCT00460694Phase 1/2
- The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple MyelomaCompletedNCT00459069Phase 1
- Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple MyelomaCompletedNCT00458653Phase 1
- A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1
- Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple MyelomaCompletedNCT00452569Phase 3
- Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid MalignanciesCompletedNCT00446342Phase 1
- GEM05 for Patients With Multiple Myeloma More Than 65 Years OldCompletedNCT00443235Phase 3
- VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the NetherlandsCompletedNCT00440765
- Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple MyelomaCompletedNCT00440635
- ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.CompletedNCT00440479
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple MyelomaStatus unknownNCT00438841Phase 2
- The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)CompletedNCT00436059Phase 2
- Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone MetastasesCompletedNCT00434447Phase 4
- A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed MyelomaStatus unknownNCT00431990Phase 1/2
- An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaCompletedNCT00431769Phase 2
- A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple MyelomaTerminatedNCT00431340Phase 2
- Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy StudiesCompletedNCT00427726
- Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple MyelomaCompletedNCT00425347Phase 1
- Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior YearCompletedNCT00424983Phase 1
- Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal MetastasesCompletedNCT00424242Early Phase 1
- Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseNo longer availableNCT00423826
- A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001bCompletedNCT00423644Phase 2
- Phase I/II Study of hLL1 in Multiple MyelomaCompletedNCT00421525Phase 1/2
- Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma PatientsCompletedNCT00417911Phase 3
- Collection of Patient-Reported Symptoms and Performance Status Via the InternetCompletedNCT00417040Not applicable
- Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney FailureCompletedNCT00416897Phase 3
- A Study of Bortezomib as Consolidation Therapy in Patients With Multiple MyelomaCompletedNCT00416273Phase 3
- Consolidation Therapy With Bortezomib in Elderly Patients With Multiple MyelomaCompletedNCT00416208Phase 3
- Hematopoietic Stem Cell Transplantation in MyelomaStatus unknownNCT00415987Phase 2/3
- Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple MyelomaCompletedNCT00415064Phase 1
- Study of Azacitidine to Treat Relapsed or Refractory Multiple MyelomaTerminatedNCT00412919Phase 2
- A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1
- Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantCompletedNCT00410657Phase 2
- Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma PatientsCompletedNCT00406978Phase 1/2
- An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00402181Phase 2
- Bortezomib-Dexamethasone-Doxorubicin-StudyCompletedNCT00401804Phase 2
- Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma PatientsCompletedNCT00401011Phase 1/2
- ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor CellsCompletedNCT00400556Phase 1
- Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.CompletedNCT00399867Phase 2
- Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00398515Phase 1
- Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple MyelomaCompletedNCT00396045Phase 1/2
- VELCADEXA: Velcade and Dexamethasone in Multiple MyelomaCompletedNCT00391157Phase 2
- Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to TreatmentStatus unknownNCT00389701Phase 2
- Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell TransplantCompletedNCT00388999Phase 1
- Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.CompletedNCT00388635Phase 1/2
- Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma PatientsStatus unknownNCT00382694Phase 2
- Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple MyelomaCompletedNCT00378768Phase 2
- Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMMStatus unknownNCT00378755Phase 2
- Autologous Transplantation for Multiple MyelomaCompletedNCT00378222Phase 3
- Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other DiseasesCompletedNCT00376922Not applicable
- Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/MonthCompletedNCT00376883Phase 3
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple MyelomaCompletedNCT00375791Phase 2
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell TransplantTerminatedNCT00369291Phase 1
- EMMA-1 (Erbitux for Multiple Myeloma)TerminatedNCT00368121Phase 2
- Treatment of Newly Diagnosed Elderly Patients With Multiple MyelomaCompletedNCT00367185Phase 3
- Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerCompletedNCT00365287Phase 1/2
- A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple MyelomaTerminatedNCT00361088Phase 1/2
- A Study of Mircera in Anemic Patients With Multiple MyelomaCompletedNCT00360347Phase 1/2
- Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma PatientsCompletedNCT00358020Phase 2
- Agriculture Health StudyActive, not recruitingNCT00352924
- A Study of ATN-224 and Bortezomib in Patients With Multiple MyelomaTerminatedNCT00352742Phase 1/2
- PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC TransplantationCompletedNCT00352703Phase 4
- TCD Followed by autoSCT for Newly Diagnosed MM PatientsStatus unknownNCT00349115Phase 2
- BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT00346255Phase 1
- Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00344422Phase 3
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Genome Expression in Lymphoma, Leukemia and Multiple MyelomaCompletedNCT00339963
- Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaTerminatedNCT00337506Phase 2
- Fluphenazine in Treating Patients With Refractory Advanced Multiple MyelomaCompletedNCT00335647Phase 1/2
- Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseCompletedNCT00335348Phase 2
- Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple MyelomaStatus unknownNCT00334932Phase 1/2
- CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell TransplantationCompletedNCT00333190Not applicable
- Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple MyelomaStatus unknownNCT00327314Phase 2
- Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma PatientsCompletedNCT00327249Phase 1/2
- Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
- A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple MyelomaCompletedNCT00323505Phase 2
- VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant CandidatesCompletedNCT00320476Phase 2
- PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple MyelomaStatus unknownNCT00319865Phase 2
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00317811Phase 2
- Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00317798Phase 1
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00316940Phase 1
- Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT00315757Phase 2
- Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple MyelomaCompletedNCT00313625Phase 2
- VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Status unknownNCT00311337Phase 2
- Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00310024Phase 1
- Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00306813Phase 1/2
- Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.CompletedNCT00306735Phase 2
- Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple MyelomaCompletedNCT00305812Phase 2
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family DonorStatus unknownNCT00304720Phase 2
- Study of XL999 in Patients With Multiple MyelomaTerminatedNCT00304590Phase 2
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
- Study of ZIO-101 in Multiple MyelomaCompletedNCT00303199Phase 1/2